Current Cancer Drug Targets

Papers
(The H4-Index of Current Cancer Drug Targets is 14. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-05-01 to 2025-05-01.)
ArticleCitations
The Expression of Glutaminases and their Association with Clinicopathological Parameters in the Head and Neck Cancers72
The Impacts of Non-coding RNAs and N6-Methyladenosine on Cancer: Past, Present and Future36
Expression, Prognostic Value, and Immune Infiltration of MTHFD Family in Bladder Cancer36
Combined RNAi of CTTN and FGF2 Modulates Cell Migration, Invasion and G1/S Transition of Hepatocellular Carcinoma through Ras/ERK Signaling Pathway25
Immune Checkpoint Inhibitors for Advanced Biliary Tract Cancer24
Identification of ATM Mutation as a Potential Prognostic Biomarker for Immune Checkpoint Inhibitors Therapy24
Silencing HEATR1 Rescues Cisplatin Resistance of Non-small Cell Lung Cancer by Inducing Ferroptosis via the p53/SAT1/ALOX15 Axis23
A Review on Patient-derived 3D Micro Cancer Approach for Drug Screen in Personalized Cancer Medicine22
Bioinformatics and Experimental Study Revealed LINC00982/ miR-183-5p/ABCA8 Axis Suppresses LUAD Progression22
TBOPP, a DOCK1 Inhibitor, Potentiates Cisplatin Efficacy in Breast Cancer by Regulating Twist-mediated EMT21
Spinal KCC2 Mediates the Modulation Effect of HDAC2 on Bone Cancer Pain in Rats20
Efficacy and Safety of Immunotherapy Combined with Anlotinib as FirstLine Treatment in Older NSCLC Patients with PD-L1 Expression<50%19
The Clinical Application of Circulating Tumor Cells and DNAs as Prognostic and Predictive Biomarkers in Gastrointestinal Cancer18
Crosstalk of Long Non-coding RNAs and EMT: Searching the Missing Pieces of an Incomplete Puzzle for Lung Cancer Therapy14
Micro-fragmented Fat Inhibits the Progression of Human Mesothelioma Xenografts in Mice14
Unveiling Novel Therapeutic Drug Targets and Prognostic Markers of Triple Negative Breast Cancer14
FHOD3 Promotes the Progression of Lung Cancer by Regulating the Caspase-3-Mediated Signaling Pathway14
A Pilot Study of Anlotinib as a Combination Treatment in Advanced Nasopharyngeal Carcinoma14
0.058931112289429